Orgenesis
21 Sparrow Circle
White Plains
New York
10605
United States
Website: http://www.orgenesis.com/
Email: info@orgenesis.com
49 articles about Orgenesis
-
Orgenesis is developing a point-of-care manufacturing platform for cell and gene and other advanced therapies to make them more widely available and significantly more affordable.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 22, 2020.
-
Orgenesis announces collaboration with the John Hopkins University for the development and processing of cell and gene based clinical therapeutics
2/19/2020
Orgenesis Inc. (NASDAQ: ORGS), a provider of point-of-care cell and gene therapy development, processing and treatment solutions (“POCare”), today announced that it has entered into a collaboration agreement with the John Hopkins University (“JHU”) to utilize Orgenesis’ Point-of-Care (POCare) platform to develop and supply a variety of cell and gene therapies and technologies, including cell-based immunotherapy technologies
-
Orgenesis completes sale of Masthercell subsidiary; receives approximately USD 127 million in net proceeds
2/11/2020
Sale reflects culmination of successful CDMO strategy initiated in 2015 and 59 percent 5-year CAGR of Masthercell under Orgenesis’ leadership
-
Orgenesis announces agreement for the sale of Masthercell Global, its contract development and manufacturing organization (CDMO) subsidiary
2/3/2020
Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), today announced that Catalent Pharma Solutions has agreed to acquire Masthercell Global, Inc., a contract development manufacturing organization (CDMO) subsidiary of Orgenesis backed by Great Point Partners and SFPI-FPIM.
-
Orgenesis appoints industry veteran Mario Philips to its board of directors
1/13/2020
Mario Philips is chief executive officer of PolyNeuroS, a drug company based in France that has developed a diagnostic platform technology for neurodegenerative diseases in combination with a therapy to cure neurodegenerative diseases such as ALS and Parkinson’s.
-
Orgenesis announces addition of University of California, Davis, to its point of care network; UC Davis Health to utilize Orgenesis’ point of care platform for the development, commercialization and supply of cell and gene therapy products
1/10/2020
First collaboration project focused on developing and commercializing lentiviral manufacturing system
-
Orgenesis and Theracell to launch Point of Care cell and gene therapy centers within HYGEIA Group’s hospital network in Greece
12/6/2019
Partnership to enable HYGEIA’s hospital network to develop and deliver onsite cell and gene therapies to patients
-
Orgenesis Ranked 5th Fastest Growing Technology Company in Maryland and 208th in North America on Deloitte's 2019 Technology Fast 500(TM)
11/29/2019
Orgenesis Inc. announced it has been ranked the 5th fastest growing technology company in Maryland and 208th in North America on Deloitte’s 2019 Technology Fast 500, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America.
-
Orgenesis CEO appears as a guest on i24 news network
11/13/2019
Orgenesis Inc. announced that Vered Caplan, CEO of Orgenesis, appeared as a guest during the “Israel Business Weekly” segment hosted by Michelle Makori and Eric Landskroner on the i24News Network.
-
Orgenesis third quarter 2019 revenue increases 46 percent to a record USD 9.1 million
11/8/2019
Generates over USD 1 million in sales through new POCare platform
-
Orgenesis announces co-development agreement with Accellix
10/16/2019
Agreement Integrates Accellix’s Proprietary Quality Control Optic System, Cartridges, Reagents and Software into Orgenesis’ Point of Care Cellular Therapy Platform
-
Orgenesis granted FDA Orphan Drug Designation for autologous insulin producing cells in the treatment of severe hypoglycemia-prone diabetes resulting from total pancreatectomy
6/17/2019
Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a developer, manufacturer and service provider of advanced cell therapies, announces that the United States Food & Drug Administration (FDA) has granted Orphan Drug designation for its Autologous Insulin Producing (AIP) cells as a cell replacement therapy for the treatment of severe hypoglycemia-prone diabetes resulting from total pancreatectomy (TP) due to chronic pancreatitis (CP)
-
Secant Group Announces Collaboration between Orgenesis and Atvio Biotech, a Wholly Owned Subsidiary of Masthercell Global, to Develop and Commercialize Scaffold Technologies for Advanced Cell Therapies
7/31/2018
Secant Group and Atvio Biotech to advance project under $1.8 million grant from the Israel-U.S. Binational Industrial R&D Foundation
-
Orgenesis Provides Update Regarding AIP Cell-Based Therapy For Type 1 Diabetes, Masthercell Cell Manufacturing Subsidiary And Overall Financial Condition
3/8/2017
-
Orgenesis Approved For Euro 12.3 Million European Grant For Further Development Of Its Type 1 Diabetes Program
2/14/2017
-
Orgenesis And Atvio Biotech Launch Joint Venture For Gene And Cell Therapy Development Services
8/1/2016
-
Orgenesis And CureCell Awarded Grant From The KORIL Fund For Diabetes Research And Development
6/7/2016
-
Orgenesis And CureCell Create Joint Venture For Contract Development And Manufacturing Of Cell Therapy Products In South Korea
6/2/2016
-
Orgenesis Approved For Additional European Grant For Further Development Of Its Type 1 Diabetes Program
4/14/2016